Nakauchi, Masaya
Vos, Elvira
Tang, Laura H.
Gonen, Mithat
Janjigian, Yelena Y.
Ku, Geoffrey Y.
Ilson, David H.
Maron, Steven B.
Yoon, Sam S.
Brennan, Murray F.
Coit, Daniel G.
Strong, Vivian E.
Funding for this research was provided by:
National Cancer Institute (P30 CA008748)
Article History
Received: 3 November 2020
Accepted: 6 January 2021
First Online: 10 February 2021
Disclosure
: Dr. Yelena Y. Janjigian has received research funding provided to the institution from Rgenix, Boehringer Ingelheim, Bayer, Genentech/Roche, Bristol-Myers Squibb, Eli Lilly, and Merck, has served on advisory boards for Rgenix, Merck Serono, Bristol-Myers Squibb, Eli Lilly, Pfizer, Bayer, Imugene, Merck, Daiichi-Sankyo, and AstraZeneca. GYK, and has received honoraria and research funding from Merck, Bristol-Myers Squibb, and Pieris and research funding from AstraZeneca, Zymeworks, and Daiichi Sankyo. Dr. David H. Ilson has received research funding from and served on advisory boards for Astellas, Eli Lilly, Pieris, and Taiho, and has served on advisory boards for Astra-Zeneca, Amgen, Bayer, Bristol-Myers Squibb, and Roche. Dr. Steven B. Maron has received research funding from Genentech and travel expenses from Merck and Bayer. The remaining authors have no conflicts of interest.